TY - JOUR
T1 - International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease
AU - Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program
AU - Tian, Mei
AU - Civelek, A. Cahid
AU - Carrio, Ignasi
AU - Watanabe, Yasuyoshi
AU - Kang, Keon Wook
AU - Murakami, Koji
AU - Garibotto, Valentina
AU - Prior, John O.
AU - Barthel, Henryk
AU - Zhou, Rui
AU - Hou, Haifeng
AU - Dou, Xiaofeng
AU - Jin, Chentao
AU - Zuo, Chuantao
AU - Zhang, Hong
N1 - Funding Information:
VG has received funding from the Velux Foundation, and the Schmidheiny Foundation and research/teaching support through her institution from Siemens Healthineers, GE Healthcare, Roche, Merck, Cerveau Technologies, and Life Molecular Imaging. The rest of the authors declare no competing interests.
Funding Information:
This study was partially sponsored by the National Natural Science Foundation of China (NSFC) (81761148029, 81725009, 82030049), Ministry of Science and Technology of China (MOST) (2021YFE0108300), Swiss National Science Foundation (project nos. 185028, 188355 and 169876) and National Research Foundation of Korea (NRF-2017K2A9A2A10013554).
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/2
Y1 - 2022/2
N2 - Purpose: Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform 18F-flortaucipir PET imaging. Method: A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for 18F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting. Conclusion: This international consensus and practice guideline will help to promote the standardized use of 18F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.
AB - Purpose: Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform 18F-flortaucipir PET imaging. Method: A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for 18F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting. Conclusion: This international consensus and practice guideline will help to promote the standardized use of 18F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.
KW - Alzheimer’s disease (AD)
KW - Brain imaging
KW - F-flortaucipir
KW - Positron emission tomography (PET)
UR - http://www.scopus.com/inward/record.url?scp=85122443769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122443769&partnerID=8YFLogxK
U2 - 10.1007/s00259-021-05673-w
DO - 10.1007/s00259-021-05673-w
M3 - Article
C2 - 34978595
AN - SCOPUS:85122443769
SN - 1619-7070
VL - 49
SP - 895
EP - 904
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 3
ER -